08/03/2016

Biohit Oyj

Simultaneous testing of GastroPanel® biomarkers is possible – preliminary study results have been completed

In accordance with the licensing agreement signed in 2013 between Biohit Oyj and clinical diagnostic company Randox Laboratories Ltd., an initial study investigating the simultaneous determination of Biohit GastroPanel® biomarkers using Randox Biochip Array Technology (BAT) has now been completed. According to preliminary study results, BAT simultaneously detects three key GastroPanel® biomarkers from a single patient sample. This multi-analytical approach would result in GastroPanel® becoming a more cost-effective, user-friendly test for diagnosis of dyspeptic symptoms and the screening of gastric cancer risk.

The Biohit GastroPanel® consists of four biomarkers: Pepsinogen I and II (PGI, PGII), Gastrin-17 (G-17) and Helicobacter pylori -antibodies. Biohit GastroPanel® is a unique Helicobacter pylori blood test providing valuable information on the health of the stomach. In addition toHelicobacter pylori infection (gastritis), this test detects atrophic gastritis with related risks, e.g. gastric and oesophageal cancer, malabsorption of vitamin B12 and a decreased acid output. Randox BAT allows the simultaneous determination of three of the GastroPanel® analytes (PGI, PGII and G-17), from a single patient sample. This is a more efficient test method compared to single analyte detection used in the previous test version. In the near future, the three analyte GastroPanel® biochip array in combination with a separate GastoPanel® biochip array for detection of Helicobacter pylori antibodies will be released and results reported through GastroSoft.

Chief Scientific Officer John Lamont, Randox Laboratories Ltd.: ‘This study indicates that Biochip Array Technology provides a robust platform for the simultaneous measurement of the unique GastroPanel® biomarkers Pepsinogen I, Pepsinogen II and Gastrin 17 from a single patient sample. Biochip Array Technology uses low sample volume and will offer a cost effective and efficient method for patient testing.’

CEO Semi Korpela, Biohit Oyj: ‘These preliminary results are promising. Simultaneous determination of GastroPanel® facilitates the reliable screening and diagnosis of Helicobacter pylori and its potential sequels, like gastric cancer and vitamin B12 deficiency, thus making GastroPanel® cost-efficient test for the use in the primary healthcare and screening.’

Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com

www.biohithealthcare.com/additional-information

www.gastropanel.com/decision-makers/screening-model
 

Biohit Oyj in brief

Biohit is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com

Randox Laboratories Ltd. in brief

Randox is an international company with over 30 years’ experience in research, development, manufacture and marketing of high quality diagnostic reagents and equipment for laboratory medicine. The range of products includes, the innovative Biochip Array Technology, clinical chemistry analysers, reagents, external quality assurance schemes, quality control materials and an extensive life sciences portfolio. Randox is dedicated to improving health worldwide and the headquarters is located in the UK. www.randox.com

Exhibitor Data Sheet